Traynor Capital Management Inc. Acquires 13,555 Shares of AbbVie Inc. $ABBV

Traynor Capital Management Inc. raised its holdings in AbbVie Inc. (NYSE:ABBV) by 222.3% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 19,653 shares of the company’s stock after purchasing an additional 13,555 shares during the period. Traynor Capital Management Inc.’s holdings in AbbVie were worth $4,550,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in ABBV. Evolution Wealth Management Inc. bought a new stake in AbbVie during the second quarter worth about $26,000. Spurstone Advisory Services LLC bought a new position in AbbVie in the 2nd quarter valued at about $28,000. Financial Gravity Companies Inc. acquired a new position in shares of AbbVie in the 2nd quarter valued at approximately $36,000. Delos Wealth Advisors LLC bought a new stake in shares of AbbVie during the 2nd quarter worth approximately $39,000. Finally, Bear Mountain Capital Inc. boosted its position in shares of AbbVie by 480.6% during the 2nd quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock worth $40,000 after acquiring an additional 173 shares in the last quarter. 70.23% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

ABBV has been the subject of several recent analyst reports. Piper Sandler restated an “overweight” rating and set a $289.00 target price (up from $284.00) on shares of AbbVie in a research note on Wednesday, November 5th. HSBC upgraded AbbVie from a “hold” rating to a “buy” rating and upped their price objective for the stock from $225.00 to $265.00 in a research report on Wednesday, December 10th. DZ Bank downgraded shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price target on the stock. in a research note on Tuesday, November 4th. Bank of America raised their target price on shares of AbbVie from $220.00 to $251.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Finally, Citigroup cut their price objective on AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a report on Tuesday. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat.com, AbbVie presently has an average rating of “Moderate Buy” and an average price target of $249.37.

AbbVie Stock Performance

Shares of AbbVie stock opened at $218.99 on Thursday. The stock has a 50 day moving average price of $224.85 and a two-hundred day moving average price of $218.01. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81. The stock has a market capitalization of $387.04 billion, a PE ratio of 165.90, a price-to-earnings-growth ratio of 0.92 and a beta of 0.36.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.77 by $0.09. The firm had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same period in the prior year, the business posted $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Research analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be paid a $1.73 dividend. The ex-dividend date is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a yield of 3.2%. AbbVie’s dividend payout ratio (DPR) is currently 524.24%.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Retrospective look: an analysis of why AbbVie outperformed in 2025 highlights management’s handling of blockbuster patent cliffs and portfolio transitions, supporting investor confidence in AbbVie’s strategy and cash returns. Why AbbVie Stock Trounced the Market in 2025
• Positive Sentiment: Berenberg raised its price target to $275 (from $270) and kept a Buy rating, citing momentum for Skyrizi and Rinvoq — a bullish signal from an institutional analyst that can support upside. Berenberg Grows More Confident in AbbVie
• Positive Sentiment: AbbVie and Novartis announced multi‑billion dollar licensing arrangements for oncology and Alzheimer’s treatments — a pipeline/collaboration boost that could add long-term revenue optionality. AbbVie and Novartis Announce Billion Dollar Licensing Deals
• Positive Sentiment: Clinical/dev updates: coverage discusses a bispecific trial win and AbbVie’s R&D commitments that could strengthen the growth narrative if results translate to approvals. Does AbbVie’s Bispecific Trial Win…
• Positive Sentiment: AbbVie completed a Phase 1 study for an on‑body injector to deliver risankizumab — operational progress that could improve dosing convenience and commercial uptake. AbbVie Advances Risankizumab Delivery
• Positive Sentiment: Allergan Aesthetics released pooled Phase 3 and Phase 4 data across injectables at IMCAS, underscoring strength in the aesthetics business line. Allergan Aesthetics Unveils New Data
• Positive Sentiment: On-air analyst support: a CNBC guest recommended staying long AbbVie, a short-term endorsement that can help sentiment. AbbVie on CNBC’s ‘Final Trades’
• Neutral Sentiment: Options activity: commentary notes unusual options movement, worth watching for short-term volatility but not definitive direction. Is the Options Market Predicting a Spike?
• Neutral Sentiment: Insider/holder note: a small asset manager disclosed a modest stake increase — a minor vote of confidence but immaterial to market cap. Belpointe Asset Management Increases Stake
• Neutral Sentiment: Corporate philanthropy: the AbbVie Foundation opened applications for a health equity accelerator — positive PR but unlikely to move the stock. AbbVie Foundation Health Equity Accelerator
• Negative Sentiment: Policy risk: CMS named several AbbVie drugs for the third cycle of Medicare Drug Price Negotiations — a direct potential headwind to pricing and margins if negotiations lower reimbursement. US Medicare names Eli Lilly, Pfizer and AbbVie drugs
• Negative Sentiment: Earnings outlook: a Zacks preview said AbbVie lacks the setup for a clear earnings beat next week — a factor that can pressure near-term multiple and stock momentum. AbbVie Reports Next Week
• Negative Sentiment: Analyst change: Citigroup trimmed its price target to $230 and moved to Neutral, signaling less near-term upside from analyst coverage. Citigroup Lowers Price Target

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.